Published March 2026

Hair Relaxer Cancer MDL 3060: Full Litigation Update for 2026

Last updated: March 2026

The hair relaxer cancer lawsuit — formally known as In re: Hair Relaxer Marketing, Sales Practices and Products Liability Litigation (MDL 3060) — has grown into one of the largest mass torts in the country. With over 11,000 plaintiffs and major pharmaceutical and consumer goods companies as defendants, 2026 is shaping up to be a decisive year for the litigation.

What Is MDL 3060?

MDL 3060 consolidates federal hair relaxer cancer lawsuits before U.S. District Judge Mary Rowland in the Northern District of Illinois (Chicago). Multidistrict litigation (MDL) is a procedural device that gathers similar lawsuits from around the country into one court for coordinated pretrial proceedings — particularly discovery and expert witness hearings. Individual plaintiffs retain their own cases but share in the common legal and scientific findings developed at the MDL level.

The lawsuits allege that chemical hair relaxers — products used predominantly by Black women for decades — contain endocrine-disrupting chemicals including phthalates, parabens, and formaldehyde-releasing preservatives. These chemicals have been linked in peer-reviewed research to uterine cancer, ovarian cancer, endometriosis, and uterine fibroids at higher rates than in women who did not use relaxers.

Key Defendants in MDL 3060

The litigation names several major consumer products companies as defendants:

• L'Oréal USA — maker of brands including Dark and Lovely, Soft Sheen, and SoftSheen-Carson products
• Strength of Nature Global — maker of African Pride, Motions, and other salon-professional brands
• Namaste Laboratories — manufacturer of ORS Olive Oil and related products
• Revlon — claims against Revlon have been complicated by its 2022 bankruptcy filing
• Various retailers and distributors who sold the products

Where the Science Stands

The scientific foundation for MDL 3060 rests primarily on a 2022 study published by the National Institutes of Health (NIH) in the Journal of the National Cancer Institute. The study analyzed data from more than 33,000 women in the Sister Study cohort and found that women who used hair straightening products more than four times in the prior year had more than double the risk of uterine cancer compared to those who never used these products. Uterine cancer diagnoses among the frequent-use group increased from 1.64% to 4.05%.

Subsequent research has supported these findings, examining the specific chemicals in relaxer formulations and their mechanisms of action as endocrine disruptors. Daubert hearings — where judges evaluate whether expert testimony meets legal standards for admissibility — are a critical milestone in 2026 that will determine which expert opinions plaintiffs can use at trial.

Bellwether Trials: The Litigation's Proving Ground

In large MDLs, courts select a small number of cases for early trial — these are called bellwether cases. The outcomes of bellwether trials provide real-world data about how juries respond to the evidence, which helps all parties assess the overall value of the litigation and often accelerates settlement discussions. Bellwether selection and scheduling in MDL 3060 is a major development to watch in 2026. Trial verdicts or strong pre-trial rulings could shift the momentum significantly.

Punitive Damages: What Was Approved

In a significant ruling, the court allowed plaintiffs to pursue punitive damages — compensation beyond actual losses designed to punish particularly wrongful conduct. This ruling signals that the court found sufficient evidence at the pleading stage that defendants may have known about the risks their products posed and continued to sell them without adequate warnings. Punitive damages can substantially increase the value of cases where egregious corporate conduct is proven.

What This Means If You're Considering Filing

MDL litigation typically moves in waves. Early plaintiffs have the most influence on how the litigation develops — their cases may be selected as bellwethers, their document requests drive discovery, and their legal teams shape the theories that become established at trial. Women who used chemical hair relaxers and later developed uterine cancer, ovarian cancer, or other qualifying conditions are still filing claims in 2026, but the window to participate as an early plaintiff is narrowing as the litigation matures toward trial and potential settlement.

If you have a qualifying diagnosis and a history of chemical hair relaxer use, getting a free case evaluation now puts you in the litigation during its formative stage — before settlement structures are set and before filing deadlines may close.